188.89 0.00 (0.00%)
After hours: 5:15PM EDT
|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||187.68 - 191.81|
|52 Week Range||142.81 - 197.00|
|Beta (3Y Monthly)||1.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018|
|Forward Dividend & Yield||2.88 (1.57%)|
|1y Target Est||214.16|
Allergan (AGN) is facing loss of exclusivity for many blockbuster products. However, drugs like Botox/Linzess, new drugs and cost cuts can shield it from potential sales drop.
Allergan PLC said early Wednesday that it plans to file for U.S. approval of its acute migraine drug, ubrogepant, by the first quarter of 2019. If all goes as expected, the company said it expects the drug will be "the first oral CGRP receptor antagonist submitted in the U.S. for the acute treatment of migraine with or without aura." A slew of new drugs have recently been approved to prevent migraine -- a chronic, debilitating condition that millions of Americans suffer from -- but Allergan's drug takes a different approach, and is intended to for so-called "acute relief," or easing the painful attacks as they occur. Existing alternatives in this space include general pain drugs and popular migraine medications called triptans. Allergan has previously said that it plans to file for Food and Drug Administration approval of ubrogepant next year; the recent completion of two clinical studies should allow it to file by the first quarter, the company said. Company shares rose 0.5% in Wednesday premarket trade. Shares have surged 7% over the last three months, compared with a 0.01% rise in the S&P 500 and a 2.7% rise in the Dow Jones Industrial Average .
DUBLIN, Oct. 17, 2018 /PRNewswire/ -- Allergan plc (AGN) today announced the completion of two positive safety and tolerability studies of ubrogepant for the acute treatment of migraine. Based on the completion of these safety studies for ubrogepant and previously reported efficacy and safety results from the ubrogepant ACHIEVE I (UBR-MD-01) and ACHIEVE II (UBR-MD-02). Allergan anticipates that the ubrogepant NDA will be the first oral CGRP receptor antagonist submitted in the U.S. for the acute treatment of migraine with or without aura.
Big pharmaceutical stocks have routinely lagged those of the biotech sector and, so far this year, are underperforming the broader health-care sector by a margin of more than 7%. Citing fading headwinds along with innovation and boosted new-drug sales, Guggenheim’s Seamus Fernandez names Merck & Co. Inc. ( MRK), Allergan PLC ( AGN) and AstraZeneca ( AZN) as three of his favorites, while also giving Eli Lilly & Co. ( LLY) and Novo Nordisk ( NVO) a buy rating, according to Barron’s.
DUBLIN and SAN FRANCISCO, Oct. 16, 2018 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360's Supplemental New Drug Application (sNDA) to extend the duration of use of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg for the prevention of pregnancy for up to five years. "A large and diverse population of women already use LILETTA as a safe, long-acting and reversible contraceptive option. This approval means that LILETTA is now indicated for up to 5 years of use.
DUBLIN , Oct. 11, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 13 abstracts at the annual American Society for Dermatologic ...
On October 3, Allergan’s (AGN) stock price closed at $193.46, which is ~11.0% below its 52-week high of $215.10 on October 3, 2017. Allergan’s stock price grew from $164.05 at the open of the market on January 2 to $193.46 on October 3, which reflects ~18.0% YTD (year-to-date) growth. On March 5, Merck hit its 52-week low of $142.81.
DUBLIN, Oct. 8, 2018 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company, today announced it will present data from its gastroenterology portfolio at the American College of Gastroenterology Annual Scientific Meeting (ACG), from October 5-10, 2018 in Philadelphia, PA. "Allergan is working to change treatment paradigms across gastroenterology with our Open Science research and development model," said David Nicholson, Chief Research and Development Officer, Allergan. Allergan will present efficacy and safety data from RELIEF, a Phase 4, multicenter, multinational, randomized, placebo-controlled, double-blind study of VIBERZI® (eluxadoline) CIV in patients with irritable bowel syndrome with diarrhea (IBS-D) who report inadequate symptom control with loperamide (poster #0344).
- New programs will evaluate the safety and efficacy of brazikumab (an investigational drug) and the potential correlation between biomarkers and patient outcomes with brazikumab - Programs are part of ...
Allergan’s (AGN) product portfolio includes generic pharmaceutical products and specialty pharmaceutical products. The company’s business comprises three segments—US General Medicines, US Specialized Therapeutics, and International. The chart below compares Allergan’s revenues and EPS since the first quarter of 2017, as well as its estimates for the third quarter.
DUBLIN, Oct. 4, 2018 /PRNewswire/ -- Allergan plc (AGN) today announced that the CoolSculpting® treatment received FDA clearance to treat the submandibular area. In addition, the FDA clearance was expanded to include patients with a BMI of up to 46.2 when treating the submental and submandibular areas. This recent clearance makes CoolSculpting® the first and only nonsurgical fat reduction treatment to contour the area below the jawline and improve the appearance of lax tissue in conjunction with submental fat treatments.
The US Pharmaceutical sector comprises drug manufacturers, drug marketers, and biotechnology companies. The chart below lists the recent mergers and acquisitions in the pharmaceuticals sector.
Paratek (PRTK) gets FDA approval for Nuzyra for the treatment of serious community-acquired bacterial infections and Seysara for the treatment of acne.
Health care gained 14.04% in the third quarter, but traders say individual names within the space are under valued and poised to move higher.
DUBLIN, Oct. 3, 2018 /PRNewswire/ -- Allergan plc (AGN) announced today the launch of a new JUVÉDERM® advertising campaign created to empower the next generation of consumers to "JUVÉDERM® IT." JUVÉDERM® IT marks the first new advertising campaign in three years for the world's #1 selling dermal filler collection1 and was designed to further Allergan's goal of making the JUVÉDERM® Collection of Fillers a first choice and household name for consumers.
Dave Goeddel helped build Genentech and Tularik and played a key role in building NGM's portfolio of drugs, including an experimental treatment for nonalcoholic steatohepatitis, or NASH.
DUBLIN , Oct. 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it intends to release third quarter 2018 financial results on Tuesday, October 30, 2018 , prior to the open of U.S. financial ...
Eli Lilly and Company (LLY) reported a top line of $6.4 billion in the second quarter, a 9% YoY (year-over-year) rise in revenue compared to $5.8 billion in the second quarter of 2017.
FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K
DUBLIN, Sept. 28, 2018 /PRNewswire/ -- In celebration of breast cancer awareness month, Allergan plc (AGN) announced today The Allergan Foundation's continuing commitment to breast health, awareness, restoration, and research through a $2,000,000 pledge to be paid over the next three years to select nonprofit organizations. Established in 1998, The Allergan Foundation is a U.S.-based, private charitable foundation committed to providing a lasting and positive impact in the communities in which Allergan employees live and work. The Allergan Foundation focuses its support on charitable efforts dedicated to promoting access to quality healthcare and improving patient diagnosis, treatment, care and quality of life. The Allergan Foundation has donated more than $84 million to charities, both domestic and abroad, since its inception. Individuals interested in learning more about The Allergan Foundation can visit AllerganFoundation.org.
FDA accepts Allergan's (AGN) sNDA for label expansion of its schizophrenia drug, Vraylar (cariprazine) to include treatment of bipolar depression.
On September 12, Allergan (AGN) announced the launch of SpotLyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit. On September 6, Allergan announced the launch of its dual-acting product, the SkinMedica Lumivive System. SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.
On September 14, Allergan (AGN) announced the acquisition of Bonti Inc., a clinical-stage biotechnology company. Bonti is a privately held company focused on developing and commercializing the neurotoxin programs for use in aesthetics and therapeutics. The chart below shows the highlights of the deal.